Article
CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance…
medRxiv · 2023 · Boumelha, J.; de Castro, A.; Bah, N.; Cha, H.; de Carne Trecesson, S.; Rana, S.; Anastasiou, P.; Mugarza, E.; Moore, C.; Goldstone, R.; East, P.; Litchfield, K.; Lee, S.-H.; Molina-Arcas, M.; Downward, J.
Key facts
| Title | CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer |
|---|---|
| First author | Boumelha, J.; de Castro, A.; Bah, N.; Cha, H.; de Carne Trecesson, S.; Rana, S.; Anastasiou, P.; Mugarza, E.; Moore, C.; Goldstone, R.; East, P.; Litchfield, K.; Lee, S.-H.; Molina-Arcas, M.; Downward, J. |
| Journal | medRxiv |
| Published | Aug 17, 2023 |
| DOI | 10.1101/2023.04.13.536740 |
| Devices mentioned | BK110039 |
| Product codes mentioned | JJH, KIP, KIT, NDS, NJT, PFF, PFT, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1